Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis

NCT06041269 is registered in ClinicalTrials.gov with AnaptysBio, Inc. as lead sponsor.

NCT NCT06041269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06041269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis
Lead sponsor
AnaptysBio, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 31, 2023
Completion date
May 30, 2025
Enrollment
420 (estimated)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis